A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

NCT05068102 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Squamous Cell of Head and Neck (HNSCC)
Melanoma
Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: BI 765063
DRUG: Ezabenlimab
DRUG: [89Zr]Zr- BI 765063
DRUG: BI 770371
DRUG: [89Zr]Zr- BI 770371

Sponsor

Boehringer Ingelheim